{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"HYPD","limit":50},"count":50,"signals":[{"ticker":"HYPD","company":"HYPERION DEFI, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":69,"context":"ely affect our business. As a result of our HYPE treasury strategy, our assets are concentrated in our HYPE holdings. Accordingly, the emergence or growth of digital assets other than HYPE may have a material adverse effect on our financial condition. There are numerous alternative digital assets and many entities, including consortiums and financial institutions, that are researching and investing resources into privat","filed_date":"2026-03-30","accession":"0001104659-26-036286","full_text":"https://origin.rootz.global/static/filing/0001104659-26-036286.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HYPD","company":"HYPERION DEFI, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":14,"context":"ing Policy can be found as Exhibit 19.1 to this Annual Report on Form 10-K. **Hedging and Pledging Transactions** Under our Insider Trading Policy, we strongly discourage our employees (including our named executive officers) and our directors from hedging our securities, holding shares of our common stock in a margin account, or pledging shares of our common stock as collateral for a loan. **Executive Officers** The fo","filed_date":"2026-03-30","accession":"0001104659-26-036286","full_text":"https://origin.rootz.global/static/filing/0001104659-26-036286.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HYPD","company":"HYPERION DEFI, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":35,"context":"y affect our business.** As a result of our HYPE treasury strategy, our assets are concentrated in our HYPE holdings. Accordingly, the emergence or growth of digital assets other than HYPE may have a material adverse effect on our financial condition. There are numerous alternative digital assets and many entities, including consortiums and financial institutions, that are researching and investing resources into privat","filed_date":"2025-12-10","accession":"0001104659-25-119843","full_text":"https://origin.rootz.global/static/filing/0001104659-25-119843.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HYPD","company":"HYPERION DEFI, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":36,"context":"y affect our business.** As a result of our HYPE treasury strategy, our assets are concentrated in our HYPE holdings. Accordingly, the emergence or growth of digital assets other than HYPE may have a material adverse effect on our financial condition. There are numerous alternative digital assets and many entities, including consortiums and financial institutions, that are researching and investing resources into privat","filed_date":"2025-11-17","accession":"0001104659-25-112966","full_text":"https://origin.rootz.global/static/filing/0001104659-25-112966.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HYPD","company":"HYPERION DEFI, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":33,"context":"ely affect our business. As a result of our HYPE treasury strategy, our assets are concentrated in our HYPE holdings. Accordingly, the emergence or growth of digital assets other than HYPE may have a material adverse effect on our financial condition. There are numerous alternative digital assets and many entities, including consortiums and financial institutions, that are researching and investing resources into privat","filed_date":"2025-11-14","accession":"0001104659-25-111671","full_text":"https://origin.rootz.global/static/filing/0001104659-25-111671.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HYPD","company":"HYPERION DEFI, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":37,"context":"ng December31, 2025 by the audit committee of the Companys Board of Directors (the Board of Directors or the Board) (Proposal 2);  3.To approve, on an advisory basis, the compensation of the Companys named executive officers as disclosed in the Proxy Statement (Proposal 3);  4.To approve an amendment to the Companys Third Amended and Restated Certificate of Incorporation, as amended (the Charter), in substantially the f","filed_date":"2025-07-24","accession":"0001104659-25-070234","full_text":"https://origin.rootz.global/static/filing/0001104659-25-070234.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HYPD","company":"HYPERION DEFI, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":14,"context":"l Officer, Treasurer and Secretary since November2024. Prior to these roles, he served as the Companys Corporate Vice President from 2018 to 2021 and the Chief Operating Officer from 2021 until being named Chief Executive Officer. Previously, Mr.Rowe was the Executive Director of Marketing for Aerie PharmaceuticalsInc., where he was pivotal in the commercialization of their glaucoma franchise. Before that, Mr.Rowe spent 12yea","filed_date":"2025-04-30","accession":"0001410578-25-001047","full_text":"https://origin.rootz.global/static/filing/0001410578-25-001047.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HYPD","company":"HYPERION DEFI, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":80,"context":"ates might not be considered medically necessary or cost effective. A decision by a third-party payor not to cover a product could reduce physician utilization once the product is approved and have a material adverse effect on sales, our operations and financial condition. Additionally, a payors decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Further,","filed_date":"2025-04-15","accession":"0001410578-25-000743","full_text":"https://origin.rootz.global/static/filing/0001410578-25-000743.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HYPD","company":"HYPERION DEFI, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":25,"context":"a foreign corporation and is in good standing under the laws of each jurisdiction which requires such qualification, except where the failure to so qualify would not reasonably be expected to have a material adverse effect on (i) the financial condition, business, properties or prospects of the Company, taken as a whole or (ii) the Companys performance of this Agreement or any of the transactions contemplated hereby (c","filed_date":"2024-12-30","accession":"0001104659-24-132482","full_text":"https://origin.rootz.global/static/filing/0001104659-24-132482.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HYPD","company":"HYPERION DEFI, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":43,"context":"g December31, 2024 by the audit committee of the Companys Board of Directors (the Board of Directors or the Board) (Proposal 2);  3. To approve, on an advisory basis, the compensation of the Companys named executive officers as disclosed in the Proxy Statement (Proposal 3);  4. To indicate, on an advisory basis, the preferred frequency of future stockholder advisory votes on the compensation of our named executive offic","filed_date":"2024-05-03","accession":"0001104659-24-056989","full_text":"https://origin.rootz.global/static/filing/0001104659-24-056989.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HYPD","company":"HYPERION DEFI, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":19,"context":"ness shall have the meaning ascribed to such term in Section 3.1(x). Liens means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction. Material Adverse Effect shall have the meaning assigned to such term in Section 3.1(b). Material Permits shall have the meaning ascribed to such term in Section 3.1(m). Participation Maximum shall have the meaning ascribed","filed_date":"2024-04-09","accession":"0001104659-24-045015","full_text":"https://origin.rootz.global/static/filing/0001104659-24-045015.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HYPD","company":"HYPERION DEFI, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":15,"context":"nt concentrations or a placebo control arm. The primary assessment of efficacy is based on reduction in myopia progression after 3years of medication use. We expect that over half of the intended enrollment of CHAPERONE will have reached the three-year efficacy endpoint in late 2024. At that time, we plan to discuss an interim analysis with the FDA to determine if there is a more efficient pathway to","filed_date":"2024-03-18","accession":"0001410578-24-000226","full_text":"https://origin.rootz.global/static/filing/0001410578-24-000226.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HYPD","company":"HYPERION DEFI, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":82,"context":"effects or have other properties that could delay or prevent their regulatory approval and limit the commercial profile of an approved label, and such side effects or other properties could result in significant negative consequences following any marketing approval of any of our product candidates. | | | | We might not be able to develop any additional marketable products utilizing our technology and we might not be able to ide","filed_date":"2024-03-18","accession":"0001410578-24-000226","full_text":"https://origin.rootz.global/static/filing/0001410578-24-000226.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HYPD","company":"HYPERION DEFI, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":25,"context":"of our common stock is entitled to one vote for each share held as of the record date with respect to all matters that may be considered at the meeting. Stockholder votes will be tabulated by persons appointed by our Board of Directors to act as inspectors of election for the meeting.  We bear the expense of soliciting proxies. Our directors, officers, and employees may also solicit proxies personally or by telephone, facsimile, o","filed_date":"2023-05-11","accession":"0001104659-23-058591","full_text":"https://origin.rootz.global/static/filing/0001104659-23-058591.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HYPD","company":"HYPERION DEFI, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":16,"context":"with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient enrollment for clinical trials, as well as in acquiring products, product candidates or other technologies that we may target to in-license or acquire in pursuit of our updated business plan. 21 Table of Con","filed_date":"2023-03-31","accession":"0001410578-23-000511","full_text":"https://origin.rootz.global/static/filing/0001410578-23-000511.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HYPD","company":"HYPERION DEFI, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":40,"context":"effects or have other properties that could delay or prevent their regulatory approval and limit the commercial profile of an approved label, and such side effects or other properties could result in significant negative consequences following any marketing approval of any of our product candidates. | | | | | We might not be able to develop marketable products utilizing our technology and we might not be able to identify and suc","filed_date":"2023-03-31","accession":"0001410578-23-000511","full_text":"https://origin.rootz.global/static/filing/0001410578-23-000511.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HYPD","company":"HYPERION DEFI, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":19,"context":"of our common stock is entitled to one vote for each share held as of the record date with respect to all matters that may be considered at the meeting. Stockholder votes will be tabulated by persons appointed by our Board of Directors to act as inspectors of election for the meeting.  We bear the expense of soliciting proxies. Our directors, officers, and employees may also solicit proxies personally or by telephone, facsimile, o","filed_date":"2022-05-02","accession":"0001104659-22-054203","full_text":"https://origin.rootz.global/static/filing/0001104659-22-054203.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HYPD","company":"HYPERION DEFI, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":22,"context":"alone or through a collaboration, or experience significant delays in doing so, our business could be materially harmed | | | | | We or our licensees may experience delays or difficulties in the enrollment and/or retention of patients in our clinical trials. | | | | | Delays in the commencement or completion of clinical testing of product candidates we are developing or may develop in the future may","filed_date":"2022-03-30","accession":"0001410578-22-000649","full_text":"https://origin.rootz.global/static/filing/0001410578-22-000649.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HYPD","company":"HYPERION DEFI, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":33,"context":"ates might not be considered medically necessary or cost effective. A decision by a third-party payor not to cover a product could reduce physician utilization once the product is approved and have a material adverse effect on sales, our operations and financial condition. Additionally, a payors decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Further,","filed_date":"2022-03-30","accession":"0001410578-22-000649","full_text":"https://origin.rootz.global/static/filing/0001410578-22-000649.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HYPD","company":"HYPERION DEFI, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":27,"context":"a foreign corporation and is in good standing under the laws of each jurisdiction which requires such qualification, except where the failure to so qualify would not reasonably be expected to have a material adverse effect on (i) the financial condition, business or properties of the Company, taken as a whole or (ii) the Companys performance of this Agreement or any of the transactions contemplated hereby (clauses (i)","filed_date":"2021-05-14","accession":"0001104659-21-066958","full_text":"https://origin.rootz.global/static/filing/0001104659-21-066958.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HYPD","company":"HYPERION DEFI, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":18,"context":"of our common stock is entitled to one vote for each share held as of the record date with respect to all matters that may be considered at the meeting. Stockholder votes will be tabulated by persons appointed by our Board of Directors to act as inspectors of election for the meeting.  We bear the expense of soliciting proxies. Our directors, officers, and employees may also solicit proxies personally or by telephone, facsimile, o","filed_date":"2021-04-30","accession":"0001104659-21-058277","full_text":"https://origin.rootz.global/static/filing/0001104659-21-058277.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HYPD","company":"HYPERION DEFI, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":18,"context":"study) to reduce the progression of myopia in children. We enrolled the first patient in the CHAPERONE study in June 2019. Due to the COVID-19 pandemic, we previously experienced delays in trial enrollment and initiation as a result of reduced clinical trial activities and operations at investigator sites. However, we have since been able to resume enrollment in the CHAPERONE study. On October 9, 20","filed_date":"2021-03-30","accession":"0001104659-21-043991","full_text":"https://origin.rootz.global/static/filing/0001104659-21-043991.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HYPD","company":"HYPERION DEFI, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":27,"context":"of operations. **Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial potential or result in significant negative consequences following any potential marketing approval.** If our product candidates are associated with undesirable side effects or have characteristics that are unexpected, we may need to abandon our developme","filed_date":"2021-03-30","accession":"0001104659-21-043991","full_text":"https://origin.rootz.global/static/filing/0001104659-21-043991.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HYPD","company":"HYPERION DEFI, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":19,"context":"of our common stock is entitled to one vote for each share held as of the record date with respect to all matters that may be considered at the meeting. Stockholder votes will be tabulated by persons appointed by our Board of Directors to act as inspectors of election for the meeting.  We bear the expense of soliciting proxies. Our directors, officers, and employees may also solicit proxies personally or by telephone, facsimile, o","filed_date":"2020-04-29","accession":"0001104659-20-052749","full_text":"https://origin.rootz.global/static/filing/0001104659-20-052749.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HYPD","company":"HYPERION DEFI, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":25,"context":"erations. ** ** **Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial potential or result in significant negative consequences following any potential marketing approval.** If our product candidates are associated with undesirable side effects or have characteristics that are unexpected, we may need to abandon our developme","filed_date":"2020-03-30","accession":"0001104659-20-040118","full_text":"https://origin.rootz.global/static/filing/0001104659-20-040118.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HYPD","company":"HYPERION DEFI, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":14,"context":"of our common stock is entitled to one vote for each share held as of the record date with respect to all matters that may be considered at the meeting. Stockholder votes will be tabulated by persons appointed by our Board of Directors to act as inspectors of election for the meeting.  We bear the expense of soliciting proxies. Our directors, officers, and employees may also solicit proxies personally or by telephone, facsimile, o","filed_date":"2019-04-30","accession":"0001144204-19-022126","full_text":"https://origin.rootz.global/static/filing/0001144204-19-022126.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HYPD","company":"HYPERION DEFI, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":25,"context":"ndidates. ** ** **Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial potential or result in significant negative consequences following any potential marketing approval.** If our product candidates are associated with undesirable side effects or have characteristics that are unexpected, we may need to abandon our developme","filed_date":"2019-03-27","accession":"0001144204-19-016350","full_text":"https://origin.rootz.global/static/filing/0001144204-19-016350.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HYPD","company":"HYPERION DEFI, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":14,"context":"of our common stock is entitled to one vote for each share held as of the record date with respect to all matters that may be considered at the meeting. Stockholder votes will be tabulated by persons appointed by our Board of Directors to act as inspectors of election for the meeting.  We bear the expense of soliciting proxies. Our directors, officers, and employees may also solicit proxies personally or by telephone, facsimile, o","filed_date":"2018-04-30","accession":"0001144204-18-023422","full_text":"https://origin.rootz.global/static/filing/0001144204-18-023422.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HYPD","company":"HYPERION DEFI, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":27,"context":"ndidates. ** ** **Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial potential or result in significant negative consequences following any potential marketing approval.** If our product candidates are associated with undesirable side effects or have characteristics that are unexpected, we may need to abandon our developme","filed_date":"2018-04-02","accession":"0001144204-18-018682","full_text":"https://origin.rootz.global/static/filing/0001144204-18-018682.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HYPD","company":"HYPERION DEFI, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":14,"context":"schedule or consistent with the clinical trial protocol and good clinical practices or other third-party organizations do not perform data collection and analysis in a timely or accurate manner;  enrollment and sample size of our clinical trials may be substantially different than estimated which may lead to longer timelines and larger expenses;  third-party clinical investigators engage in activitie","filed_date":"2018-01-11","accession":"0001571049-18-000024","full_text":"https://origin.rootz.global/static/filing/0001571049-18-000024.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HYPD","company":"HYPERION DEFI, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":27,"context":"duct candidates.  Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial potential or result in significant negative consequences following any potential marketing approval.  If our product candidates are associated with undesirable side effects or have characteristics that are unexpected, we may need to abandon our developmen","filed_date":"2018-01-11","accession":"0001571049-18-000024","full_text":"https://origin.rootz.global/static/filing/0001571049-18-000024.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HYPD","company":"HYPERION DEFI, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":92,"match_count":9,"context":"results for the applicable reporting period, which may create significant volatility in our reported earnings. Any decrease in reported earnings or increased volatility of such earnings could have a material adverse effect on the market price of our securities. In addition, the application of generally accepted accounting principles in the United States with respect to digital assets remains uncertain in some respects,","filed_date":"2025-08-13","accession":"0001410578-25-001740","full_text":"https://origin.rootz.global/static/filing/0001410578-25-001740.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HYPD","company":"HYPERION DEFI, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":88,"match_count":11,"context":"ise additional money to fund our operations for the next twelve months as a going concern; | | |  | | risks of our clinical trials including, but not limited to, the costs, design, initiation and enrollment (which could be adversely impacted by the coronavirus pandemic and resulting social distancing), timing, progress and results of such trials; | | |  | | our expectations related to the use of proc","filed_date":"2020-03-30","accession":"0001104659-20-040118","full_text":"https://origin.rootz.global/static/filing/0001104659-20-040118.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HYPD","company":"HYPERION DEFI, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":64,"match_count":8,"context":"s away from the HYPE ecosystem. Advancements in AI and blockchain technology are likely to accelerate the development of such protocols, including the development of additional networks that natively integrate AI into consensus mechanisms and other core features. If HYPE is unable to evolve to address such increased competition or if Layer 2 networks believe that HYPEs core technology stack is outdated or less att","filed_date":"2026-03-30","accession":"0001104659-26-036286","full_text":"https://origin.rootz.global/static/filing/0001104659-26-036286.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HYPD","company":"HYPERION DEFI, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":64,"match_count":8,"context":"nical trial. If the primary objectives of our PhaseIII program are met, we plan to submit a New Drug Application, or NDA, for marketing approval of MicroProst for the treatment of CACG in the U.S. We entered into a licensing partnership for our MicroProst program with Senju Pharmaceuticals for Asia, including China where CACG accounts for up to 50% of all glaucoma.  MicroStat  MicroStat is the potentially first-in-class fixed combin","filed_date":"2018-01-11","accession":"0001571049-18-000024","full_text":"https://origin.rootz.global/static/filing/0001571049-18-000024.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HYPD","company":"HYPERION DEFI, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":56,"match_count":7,"context":"n the form attached hereto as ExhibitA), which Note shall provide substantially as follows: principal shall be fully amortized over the applicable Amortization Period in equal, monthly principal installments plus, in each case, unpaid interest thereon at the Designated Rate (such unpaid interest, **Cash Interest**), commencing after the Interest-only Period of interest-only installments of Cash Inter","filed_date":"2025-02-24","accession":"0001104659-25-016375","full_text":"https://origin.rootz.global/static/filing/0001104659-25-016375.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HYPD","company":"HYPERION DEFI, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":56,"match_count":7,"context":"N BENEFICIAL OWNERS AND MANAGEMENT  The following table sets forth certain information with respect to the beneficial ownership of our common stock as of December2, 2024, for (a)our directors, (b)our named executive officers, (c)our executive officers and directors as a group, and (d)each stockholder known to us to beneficially own more than fivepercent of our common stock.  The number of common shares beneficially owne","filed_date":"2024-12-23","accession":"0001104659-24-130974","full_text":"https://origin.rootz.global/static/filing/0001104659-24-130974.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HYPD","company":"HYPERION DEFI, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":56,"match_count":7,"context":"with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient enrollment for clinical trials, as well as in acquiring products, product candidates or other technologies that we may target to in-license or acquire in pursuit of our updated business plan. For MicroStat,","filed_date":"2019-03-27","accession":"0001144204-19-016350","full_text":"https://origin.rootz.global/static/filing/0001144204-19-016350.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HYPD","company":"HYPERION DEFI, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":56,"match_count":7,"context":"with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient enrollment for clinical trials, as well as in acquiring products, product candidates or other technologies that we may target to in-license or acquire in pursuit of our updated business plan. For the MicroPr","filed_date":"2018-04-02","accession":"0001144204-18-018682","full_text":"https://origin.rootz.global/static/filing/0001144204-18-018682.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HYPD","company":"HYPERION DEFI, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":54,"match_count":3,"context":"ement and execute our business strategy; our exposure to foreign currency fluctuations; reputational risk; and constraints, volatility, or disruption in the capital markets, any of which could have a material adverse effect on our business, results of operations, cash flows and financial condition. The continuing worldwide implications of the war between Russia and Ukraine and the conflict in the Middle East and between","filed_date":"2025-05-19","accession":"0001410578-25-001361","full_text":"https://origin.rootz.global/static/filing/0001410578-25-001361.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HYPD","company":"HYPERION DEFI, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":48,"match_count":6,"context":"e of microdose therapeutics in areas of key fro nt and back - of - the - eye indications Validated microdosing approach through multiple Phase II/III studies Progressive Myopia : Complete patient enrollment for Phase III CHAPERONE study in 2020 Presbyopia : Initiate and complete Phase III VISION studies in 2020 Pharmacologic Mydriasis : Phase III studies successful, New Drug Application to be submitt","filed_date":"2019-11-19","accession":"0001104659-19-065242","full_text":"https://origin.rootz.global/static/filing/0001104659-19-065242.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HYPD","company":"HYPERION DEFI, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":40,"match_count":5,"context":"s and warranties of Investors contained in this Subscription Agreement are true and correct in all material respects (other than representations and warranties that are qualified as to materiality or Material Adverse Effect, which representations and warranties shall be true in all respects) at and as of the Closing Date, and consummation of the Closing shall constitute a reaffirmation by Investors of each of the repres","filed_date":"2024-11-25","accession":"0001104659-24-122380","full_text":"https://origin.rootz.global/static/filing/0001104659-24-122380.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HYPD","company":"HYPERION DEFI, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":40,"match_count":5,"context":"he Company received cash proceeds of $463,353 pursuant to a loan provided in connection with the Paycheck Protection Program under the CARES Act (the PPP Loan). The PPP Loan provided for monthly installment payments of $19,508 beginning in August 2021 with the remaining balance due on May 3, 2022, the maturity date. The PPP Loan incurred interest at a fixed rate of 1.00% per annum. Under the terms of","filed_date":"2021-11-12","accession":"0001104659-21-138092","full_text":"https://origin.rootz.global/static/filing/0001104659-21-138092.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HYPD","company":"HYPERION DEFI, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":40,"match_count":5,"context":"ition, such statements could be affected by risks and uncertainties related to, among other things : risks of our clinical trials, including, but not limited to, the costs, design, initiation and enrollment (which could still be adversely impacted by COVID - 19 and resulting social distancing), timing, progress and results of such trials ; the timing of, and our ability to submit applications for, ob","filed_date":"2021-10-25","accession":"0001104659-21-129510","full_text":"https://origin.rootz.global/static/filing/0001104659-21-129510.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HYPD","company":"HYPERION DEFI, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":40,"match_count":5,"context":"he Company received cash proceeds of $463,353 pursuant to a loan provided in connection with the Paycheck Protection Program under the CARES Act (the PPP Loan). The PPP Loan provides for monthly installment payments of $19,508 beginning in August 2021 with the remaining balance due on May 3, 2022, the maturity date. The PPP Loan bears interest at a fixed rate of 1.00% per annum. Under the terms of th","filed_date":"2021-08-12","accession":"0001104659-21-104176","full_text":"https://origin.rootz.global/static/filing/0001104659-21-104176.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HYPD","company":"HYPERION DEFI, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":32,"match_count":4,"context":"with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient enrollment for clinical trials, as well as in acquiring products, product candidates or other technologies that we may target to in-license or acquire in pursuit of our updated business plan. For Mydcombi, w","filed_date":"2025-04-15","accession":"0001410578-25-000743","full_text":"https://origin.rootz.global/static/filing/0001410578-25-000743.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HYPD","company":"HYPERION DEFI, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":32,"match_count":4,"context":"d Against | | |  Shares Abstaining | | |  Broker Non-Votes | | | |  | 27,980,022 | | |  | 897,793 | | |  | 272,698 | | |  | 0 | | | 3. Approval, on an advisory basis, of the compensation of Eyenovias named executive officers. |  Shares Voted For | | |  Shares Voted Against | | |  Shares Abstaining | | |  Broker Non-votes | | | |  | 12,152,261 | | |  | 1,188,271 | | |  | 197,608 | | |  | 15,612,373 | | | 4. Recommendatio","filed_date":"2024-06-14","accession":"0001104659-24-071527","full_text":"https://origin.rootz.global/static/filing/0001104659-24-071527.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HYPD","company":"HYPERION DEFI, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":32,"match_count":4,"context":", a tender offer followed by a reverse merger) in which the Company is the surviving entity but (A) the Shares outstanding immediately prior to such merger are converted or exchanged by virtue of the merger into other property, whether in the form of securities, cash or otherwise, or (B) in which securities possessing more than 50% of the total combined voting power of the Companys outstanding securities are","filed_date":"2023-06-27","accession":"0001104659-23-075268","full_text":"https://origin.rootz.global/static/filing/0001104659-23-075268.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HYPD","company":"HYPERION DEFI, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":32,"match_count":4,"context":"exercise price of $1.66 per share. The options vest as follows: (i) one-third of the shares vest on the one-year anniversary of the issuance date; and (ii) the remaining two-thirds vest in equal installments beginning 13 months from the issuance date and ending 36 months from the issuance date. The fair value of the options will be recognized over the vesting period. At-the-Market Offering Program Su","filed_date":"2022-08-11","accession":"0001410578-22-002278","full_text":"https://origin.rootz.global/static/filing/0001410578-22-002278.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"HYPD","company":"HYPERION DEFI, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":32,"match_count":4,"context":", a tender offer followed by a reverse merger) in which the Company is the surviving entity but (A) the Shares outstanding immediately prior to such merger are converted or exchanged by virtue of the merger into other property, whether in the form of securities, cash or otherwise, or (B) in which securities possessing more than 50% of the total combined voting power of the Companys outstanding securities are","filed_date":"2022-06-17","accession":"0001104659-22-072110","full_text":"https://origin.rootz.global/static/filing/0001104659-22-072110.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"6be934dc444271482f45b98fcdbc114783624c9d02dc84acc93356335f70db02","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"fa35fed8c773ad75063208278beeaca47452b49c1ffa4dcf749d2bb5c9eacc66","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":69,"hourly_limit":500,"remaining":431,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}